{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:57:52Z","timestamp":1794535072264,"version":"4.9.1"},"reference-count":81,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babes University of Medicine and Pharmacy Timisoara"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited. Psychedelic-assisted therapy (PAT), integrating psychedelic substances with psychotherapy, offers a promising alternative by addressing underlying neural mechanisms. Materials and Methods: This review\u2019s purpose is to investigate the current understanding of psychedelic therapy for treating SUDs, including tobacco, alcohol, and drug addiction. The systematic review approach focused on clinical trials and randomized controlled trials conducted from 2013 to 2023. The search was performed using PubMed, Google Scholar, and Consensus AI, following PRISMA guidelines. Studies involving psychedelics like LSD, psilocybin, ibogaine, and ayahuasca for treating various addictions were included, excluding naturalistic studies and reviews. Results: Our results highlight the key findings from 16 clinical trials investigating psychedelic therapy for SUDs. Psychedelics like psilocybin and ayahuasca showed promise in reducing alcohol and tobacco dependence, with psilocybin being particularly effective in decreasing cravings and promoting long-term abstinence. The studies revealed significant improvements in substance use reduction, especially when combined with psychotherapy. However, the variability in dosages and study design calls for more standardized approaches. These findings emphasize the potential of psychedelics in SUD treatment, though further large-scale research is needed to validate these results and develop consistent protocols. Conclusions: This research reviewed the past decade\u2019s international experience, emphasizing the growing potential of psychedelic therapy in treating SUDs pertaining to alcohol, tobacco, and cocaine dependence. Psychedelics such as psilocybin and ketamine can reduce cravings and promote psychological well-being, especially when combined with psychotherapy. However, regulatory barriers and specialized clinical training are necessary to integrate these therapies into mainstream addiction treatment safely. Psychedelics offer a promising alternative for those unresponsive to conventional methods.<\/jats:p>","DOI":"10.3390\/medicina61020278","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:30:29Z","timestamp":1738823429000},"page":"278","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2185-3008","authenticated-orcid":false,"given":"Lavinia","family":"Hogea","sequence":"first","affiliation":[{"name":"Neuroscience Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Neuropsychology and Behavioral Medicine Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana C\u0103t\u0103lina","family":"Tabugan","sequence":"additional","affiliation":[{"name":"Neuroscience Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8952-3486","authenticated-orcid":false,"given":"Iuliana","family":"Costea","sequence":"additional","affiliation":[{"name":"Psychology Department, West Univerity of Timisoara, 300223 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-5104","authenticated-orcid":false,"given":"Oana","family":"Albai","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Neuroscience Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-3714","authenticated-orcid":false,"given":"Adriana","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Neuroscience Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Corsaro","sequence":"additional","affiliation":[{"name":"Campus Bio Medico, 00128 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Anghel","sequence":"additional","affiliation":[{"name":"Neuroscience Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Neuropsychology and Behavioral Medicine Center, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.addicn.2022.100025","article-title":"Classic and Non-classic Psychedelics for Substance Use Disorder: A Review of Their Historic, Past and Current Research","volume":"3","author":"Mendes","year":"2022","journal-title":"Addict. Neurosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.drugalcdep.2016.02.005","article-title":"Network Analysis of Substance Abuse and Dependence Symptoms","volume":"161","author":"Rhemtulla","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"ref_3","unstructured":"United Nations: Office on Drugs and Crime (2023). World Drug Report 2023, United Nations."},{"key":"ref_4","unstructured":"World Health Organization (2024, March 15). Fact Sheet on Alcohol Consumption, Alcohol-Attributable Harm and Alcohol Policy Responses in European Union Member States, Norway and Switzerland. Available online: https:\/\/www.who.int\/europe\/publications\/m\/item\/fact-sheet-on-alcohol-consumption--alcohol-attributable-harm-and-alcohol-policy-responses-in-european-union-member-states--norway-and-switzerland-(2018)."},{"key":"ref_5","unstructured":"(2024). Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders, World Health Organization. CC BY-NC-SA 3.0 IGO."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The Abuse Potential of Medical Psilocybin According to the 8 Factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic Hallucinogens in the Treatment of Addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, Regional, and National Comparative Risk Assessment of 79 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks, 1990\u20132015: A Systematic Analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Forouzanfar","year":"2016","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HRP.0000000000000271","article-title":"Substance Use Disorders in Global Mental Health Delivery: Epidemiology, Treatment Gap, and Implementation of Evidence-Based Treatments","volume":"28","author":"Connery","year":"2020","journal-title":"Harv. Rev. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1111\/acer.12884","article-title":"Clinical Neuroscience of Addiction: Similarities and Differences Between Alcohol and Other Drugs","volume":"39","author":"Karoly","year":"2015","journal-title":"Alcoholism. Clin. Exp. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The Current Status of Psychedelics in Psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zafar, R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M., Nutt, D.J., and Erritzoe, D. (2023). Psychedelic Therapy in the Treatment of Addiction: The Past, Present and Future. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1183740"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cobeha.2016.10.009","article-title":"Tripping up Addiction: The Use of Psychedelic Drugs in the Treatment of Problematic Drug and Alcohol Use","volume":"13","author":"Morgan","year":"2017","journal-title":"Curr. Opin. Behav. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as Medicines: An Emerging New Paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharma. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: Where We Are Now, Why We Got Here, What We Must Do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic Effects of Classic Serotonergic Psychedelics: A Systematic Review of Modern-era Clinical Studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-Term Effects of Psychedelic Drugs: A Systematic Review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic Psychedelics: An Integrative Review of Epidemiology, Therapeutics, Mystical Experience, and Brain Network Function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Black, T. (2023). Lifeboat Ethics, Risk, and Therapeutic Opportunity: An Appeal for Equitable Psychedelic Therapy Access in the \u201cHigh-Risk\u201d Addiction Patient. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1159843"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106976","DOI":"10.1016\/j.cct.2022.106976","article-title":"Psilocybin for Alcohol Use Disorder: Rationale and Design Considerations for a Randomized Controlled Trial","volume":"123","author":"Mennenga","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1037\/adb0000935","article-title":"Reports of Self-Compassion and Affect Regulation in Psilocybin-Assisted Therapy for Alcohol Use Disorder: An Interpretive Phenomenological Analysis","volume":"38","author":"Nielson","year":"2024","journal-title":"Psychol. Addict. Behav."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-Assisted Treatment for Alcohol Dependence: A Proof-of-Concept Study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/cpdd.254","article-title":"Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients","volume":"5","author":"Glue","year":"2016","journal-title":"Clin. Pharm. Drug Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/02791072.2013.873157","article-title":"Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence\u2014Qualitative Results","volume":"46","author":"Verres","year":"2014","journal-title":"J. Psychoact. Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","article-title":"Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction","volume":"7","author":"Griffiths","year":"2015","journal-title":"CDAR"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/15733998113099990003","article-title":"Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada","volume":"6","author":"Thomas","year":"2013","journal-title":"Curr. Drug Abuse. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A Sub-Set of Psychoactive Effects May Be Critical to the Behavioral Impact of Ketamine on Cocaine Use Disorder: Results from a Randomized, Controlled Laboratory Study","volume":"142","author":"Dakwar","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-Term Follow-up of Psilocybin-Facilitated Smoking Cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic Therapy for Smoking Cessation: Qualitative Analysis of Participant Accounts","volume":"32","author":"Noorani","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s40429-021-00401-8","article-title":"Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy","volume":"9","author":"Koslowski","year":"2021","journal-title":"Curr. Addict. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","article-title":"How LSD Originated","volume":"11","author":"Hofmann","year":"1979","journal-title":"J. Psychedelic Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","article-title":"A Controlled Comparison of Lysergic Acid Diethylamide (LSD) and Dextroamphetamine in Alcoholics","volume":"125","author":"Hollister","year":"1969","journal-title":"AJP"},{"key":"ref_35","unstructured":"Grinspoon, L., and Bakalar, J.B. (1979). Psychedelic Drugs Reconsidered, Basic Books."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/0004867421998785","article-title":"Medicinal Psychedelics for Mental Health and Addiction: Advancing Research of an Emerging Paradigm","volume":"55","author":"Perkins","year":"2021","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic Acid Diethylamide (LSD) for Alcoholism: Meta-Analysis of Randomized Controlled Trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"ref_38","unstructured":"Series, T. (1984). Treaties and Internationalagreements Registered Orfiled and Recorded with the Secretariatof the United Nations, United Nations."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"De Vos, C.M.H., Mason, N.L., and Kuypers, K.P.C. (2021). Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front. Psychiatry, 12.","DOI":"10.3389\/fpsyt.2021.724606"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Calleja-Conde, J., Morales-Garc\u00eda, J.A., Echeverry-Alzate, V., B\u00fchler, K.M., Gin\u00e9, E., and L\u00f3pez-Moreno, J.A. (2022). Classic Psychedelics and Alcohol Use Disorders: A Systematic Review of Human and Animal Studies. Addict. Biol., 27.","DOI":"10.1111\/adb.13229"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","article-title":"Default Mode Network Modulation by Psychedelics: A Systematic Review","volume":"26","author":"Gattuso","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Garcia-Romeu, A., Davis, A.K., Erowid, E., Erowid, F., Griffiths, R.R., and Johnson, M.W. (2020). Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Front. Psychiatry, 10.","DOI":"10.3389\/fpsyt.2019.00955"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/ajad.13461","article-title":"Addiction Specialists\u2019 Attitudes toward Psychedelics: A National Survey","volume":"32","author":"Kim","year":"2023","journal-title":"Am. J. Addict."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/02698811211058923","article-title":"MDMA\/Ecstasy Use and Psilocybin Use Are Associated with Lowered Odds of Psychological Distress and Suicidal Thoughts in a Sample of US Adults","volume":"36","author":"Jones","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"109610","DOI":"10.1016\/j.neuropharm.2023.109610","article-title":"Psychedelics: Threshold of a Therapeutic Revolution","volume":"236","author":"Heal","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103818","DOI":"10.1016\/j.drudis.2023.103818","article-title":"Psychedelic Renaissance: Revitalized Potential Therapies for Psychiatric Disorders","volume":"28","author":"Rhee","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future","volume":"42","author":"Goodwin","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_48","unstructured":"International Narcotics Control Board (2024, March 20). INCB Press Kit 2020. Available online: https:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2020\/Press_Kit\/INCB_press_kit_E.pdf."},{"key":"ref_49","unstructured":"Schultes, R.E., and Hofmann, A. (1992). Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers, Food and Agriculture Organization."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","article-title":"Psilocybin\u2013Summary of Knowledge and New Perspectives","volume":"24","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.9740\/mhc.2017.01.024","article-title":"Clinical Potential of Psilocybin as a Treatment for Mental Health Conditions","volume":"7","author":"Daniel","year":"2017","journal-title":"Ment. Health Clin."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ray, T.S. (2010). Psychedelics and the Human Receptorome. PLoS ONE, 5.","DOI":"10.1371\/annotation\/e580a864-cf13-40c2-9bd9-b9687a6f0fe4"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The Pharmacology of Lysergic Acid Diethylamide: A Review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF02245940","article-title":"LSD and Structural Analogs: Pharmacological Evaluation at D1 Dopamine Receptors","volume":"118","author":"Watts","year":"1995","journal-title":"Psychopharmacology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/shm\/hkl039","article-title":"\u2018Hitting Highs at Rock Bottom\u2019: LSD Treatment for Alcoholism, 1950\u20131970","volume":"19","author":"Dyck","year":"2006","journal-title":"Soc. Hist. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/02791072.1980.10471430","article-title":"History and Pharmacology of PCP and PCP-Related Analogs","volume":"12","author":"Domino","year":"1980","journal-title":"J. Psychedelic Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the Treatment of Addiction: Evidence and Potential Mechanisms","volume":"142","author":"Lawn","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Strong, C.E., and Kabbaj, M. (2020). Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder. Front. Behav. Neurosci., 14.","DOI":"10.3389\/fnbeh.2020.593860"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","article-title":"Monoamine Oxidase Inhibitors in South American Hallucinogenic Plants: Tryptamine and \u03b2-Carboline Constituents of Ayahuasca","volume":"10","author":"McKenna","year":"1984","journal-title":"J. Ethnopharmacol."},{"key":"ref_61","unstructured":"McKenna, D.J. (2007). The Healing Vine: Ayahuasca as Medicine in the 21st Century, APA PsycNet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.physbeh.2015.01.032","article-title":"Effects of Ayahuasca on the Development of Ethanol-Induced Behavioral Sensitization and on a Post-Sensitization Treatment in Mice","volume":"142","author":"Santos","year":"2015","journal-title":"Physiol. Behav."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/02791072.2005.10399794","article-title":"Report on Psychoactive Drug Use Among Adolescents Using Ayahuasca Within a Religious Context","volume":"37","author":"Grob","year":"2005","journal-title":"J. Psychoact. Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugalcdep.2010.03.024","article-title":"Assessment of Addiction Severity among Ritual Users of Ayahuasca","volume":"111","author":"Fondevila","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/BF01291787","article-title":"Neuropharmacological Characterization of Local Ibogaine Effects on Dopamine Release","volume":"103","author":"Reid","year":"1996","journal-title":"J. Neural. Transm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/psychoactives2040024","article-title":"Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings","volume":"2","author":"Rocha","year":"2023","journal-title":"Psychoactives"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/anoc.12119","article-title":"The Ibogaine Experience: A Qualitative Study on the Acute Subjective Effects of Ibogaine","volume":"31","author":"Kohek","year":"2020","journal-title":"Anthr. Conscious."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","article-title":"Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures","volume":"914","author":"Mash","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Mash, D.C., Duque, L., Page, B., and Allen-Ferdinand, K. (2018). Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00529"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-up Observational Study","volume":"44","author":"Noller","year":"2018","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1556\/2054.01.2017.009","article-title":"Subjective Effectiveness of Ibogaine Treatment for Problematic Opioid Consumption: Short- and Long-Term Outcomes and Current Psychological Functioning","volume":"1","author":"Davis","year":"2017","journal-title":"J. Psychedelic Stud."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin Produces Substantial and Sustained Decreases in Depression and Anxiety in Patients with Life-Threatening Cancer: A Randomized Double-Blind Trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/archpsyc.1973.01750360040005","article-title":"Residential Psychedelic (LSD) Therapy for the Narcotic Addict: A Controlled Study","volume":"28","author":"Savage","year":"1973","journal-title":"Arch. Gen Psychiatry"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1570159X16666180125095902","article-title":"Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness","volume":"17","author":"Hamill","year":"2019","journal-title":"CN"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Rush, B., Marcus, O., Garc\u00eda, S., Loizaga-Velder, A., Loewinger, G., Spitalier, A., and Mendive, F. (2021). Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.659644"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/heapro\/16.3.255","article-title":"Effectiveness of a Cognitive Behaviour Therapy Self-Help Programme for Smokers in London, UK","volume":"16","author":"Sykes","year":"2001","journal-title":"Health Promot. Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/eurheartj\/ehn552","article-title":"Behavioural Interventions for Smoking Cessation: A Meta-Analysis of Randomized Controlled Trials","volume":"30","author":"Mottillo","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/dar.12985","article-title":"Exploring Ayahuasca-assisted Therapy for Addiction: A Qualitative Analysis of Preliminary Findings among an Indigenous Community in Canada","volume":"38","author":"Argento","year":"2019","journal-title":"Drug Alcohol Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41386-022-01479-y","article-title":"Low Doses of Lysergic Acid Diethylamide (LSD) Increase Reward-Related Brain Activity","volume":"48","author":"Glazer","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics Promote Structural and Functional Neural Plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/278\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:27:51Z","timestamp":1760027271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/2\/278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["medicina61020278"],"URL":"https:\/\/doi.org\/10.3390\/medicina61020278","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}